Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus ISOPTO CETAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus ISOPTO CETAMIDE.
BLEPH-10 vs ISOPTO CETAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic